SS
TLX

Steve Schonfeld’s Telix Pharmaceuticals TLX Stock Holding History

Steve Schonfeld’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,873
Closed -$334K – 3109
2026
Q1 		$334K Buy
+34,873
New +$266K ﹤0.01% 1533

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Steve Schonfeld's TLX Position: Q2 2026 in Review

Steve Schonfeld sold out of Telix Pharmaceuticals (TLX) in Q2 2026, closing a stake of 34,873 shares — an estimated $334K sold.

Steve Schonfeld first reported a position in TLX in Q1 2026 and held it in 1 quarter. The position peaked at $334K in Q1 2026. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Steve Schonfeld reported no remaining Telix Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 34,873 Telix Pharmaceuticals shares in Q2 2026, an estimated $334K.
  • Steve Schonfeld first reported a position in Telix Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Steve Schonfeld's Telix Pharmaceuticals position peaked at $334K in Q1 2026.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.